Literature DB >> 7790092

Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli.

M A Clayton1, J M Clayton, D R Brown, J L Middlebrook.   

Abstract

A completely synthetic gene encoding fragment C, a approximately 50-kDa fragment, of botulinum neurotoxin serotype A was constructed from oligonucleotides. The gene was expressed in Escherichia coli, and full-sized product was produced as judged by Western blot (immunoblot) analysis. Crude extracts of E. coli expressing the gene were used to vaccinate mice and evaluate their survival against challenge with active toxin. Mice given three subcutaneous vaccinations were protected against an intraperitoneal administration of 10(6) 50% lethal doses (ID50) of serotype A toxin. The same mice survived when challenged with 3 LD50 of botulinum toxin serotype E but died when challenged with 10 LD50 of serotype E or 3 LD50 of serotype B. Purified fragment C was compared with the botulinum toxoid vaccine in a vaccination and challenge study. Fragment C was as efficacious in protecting against challenge with active botulinum neurotoxin serotype A as the toxoid vaccine. This recombinant protein product has many properties that make it a good candidate for human use to protect against botulinum toxin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7790092      PMCID: PMC173366          DOI: 10.1128/iai.63.7.2738-2742.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  12 in total

1.  High-level expression of tetanus toxin fragment C in Pichia pastoris strains containing multiple tandem integrations of the gene.

Authors:  J J Clare; F B Rayment; S P Ballantine; K Sreekrishna; M A Romanos
Journal:  Biotechnology (N Y)       Date:  1991-05

2.  Clostridial neurotoxins--proposal of a common nomenclature.

Authors:  H Niemann
Journal:  Toxicon       Date:  1992-03       Impact factor: 3.033

3.  Synthesis of tetanus toxin fragment C in insect cells by use of a baculovirus expression system.

Authors:  I G Charles; B C Rodgers; A J Makoff; S N Chatfield; D E Slater; N F Fairweather
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

4.  A rapid alkaline extraction procedure for screening recombinant plasmid DNA.

Authors:  H C Birnboim; J Doly
Journal:  Nucleic Acids Res       Date:  1979-11-24       Impact factor: 16.971

5.  A simple method to recover intact high molecular weight RNA and DNA after electrophoretic separation in low gelling temperature agarose gels.

Authors:  L Wieslander
Journal:  Anal Biochem       Date:  1979-10-01       Impact factor: 3.365

6.  Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli.

Authors:  N F Fairweather; V A Lyness; D J Maskell
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

7.  Expression of tetanus toxin fragment C in yeast: gene synthesis is required to eliminate fortuitous polyadenylation sites in AT-rich DNA.

Authors:  M A Romanos; A J Makoff; N F Fairweather; K M Beesley; D E Slater; F B Rayment; M M Payne; J J Clare
Journal:  Nucleic Acids Res       Date:  1991-04-11       Impact factor: 16.971

8.  Clostridial neurotoxins: new tools for dissecting exocytosis.

Authors:  H Niemann; J Blasi; R Jahn
Journal:  Trends Cell Biol       Date:  1994-05       Impact factor: 20.808

9.  Cloning, nucleotide sequencing, and expression of tetanus toxin fragment C in Escherichia coli.

Authors:  N F Fairweather; V A Lyness; D J Pickard; G Allen; R O Thomson
Journal:  J Bacteriol       Date:  1986-01       Impact factor: 3.490

10.  Expression of tetanus toxin fragment C in E. coli: high level expression by removing rare codons.

Authors:  A J Makoff; M D Oxer; M A Romanos; N F Fairweather; S Ballantine
Journal:  Nucleic Acids Res       Date:  1989-12-25       Impact factor: 16.971

View more
  40 in total

1.  High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A.

Authors:  D D Pless; E R Torres; E K Reinke; S Bavari
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

2.  Epitope mapping of neutralizing botulinum neurotoxin A antibodies by phage display.

Authors:  B P Mullaney; M G Pallavicini; J D Marks
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

3.  Vaccination of rabbits with an alkylated toxoid rapidly elicits potent neutralizing antibodies against botulinum neurotoxin serotype B.

Authors:  Daniel M Held; Amy C Shurtleff; Scott Fields; Christopher Green; Julie Fong; Russell G A Jones; Dorothea Sesardic; Roland Buelow; Rae Lyn Burke
Journal:  Clin Vaccine Immunol       Date:  2010-04-21

4.  Characterization of botulinum neurotoxin type A neutralizing monoclonal antibodies and influence of their half-lives on therapeutic activity.

Authors:  Christelle Mazuet; Julie Dano; Michel R Popoff; Christophe Créminon; Hervé Volland
Journal:  PLoS One       Date:  2010-08-26       Impact factor: 3.240

5.  Subunit vaccine efficacy against Botulinum neurotoxin subtypes.

Authors:  James S Henkel; William H Tepp; Amanda Przedpelski; Robert B Fritz; Eric A Johnson; Joseph T Barbieri
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

6.  Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system.

Authors:  R Zichel; A Mimran; A Keren; A Barnea; I Steinberger-Levy; D Marcus; A Turgeman; S Reuveny
Journal:  Clin Vaccine Immunol       Date:  2010-03-31

7.  DNA vaccines targeting heavy chain C-terminal fragments of Clostridium botulinum neurotoxin serotypes A, B, and E induce potent humoral and cellular immunity and provide protection from lethal toxin challenge.

Authors:  Veronica L Scott; Daniel O Villarreal; Natalie A Hutnick; Jewell N Walters; Edwin Ragwan; Khalil Bdeir; Jian Yan; Niranjan Y Sardesai; Adam C Finnefrock; Danilo R Casimiro; David B Weiner
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

8.  Enhancing toxin-based vaccines against botulism.

Authors:  Amanda Przedpelski; William H Tepp; Madison Zuverink; Eric A Johnson; Sabine Pellet; Joseph T Barbieri
Journal:  Vaccine       Date:  2018-01-04       Impact factor: 3.641

9.  Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system.

Authors:  YunZhou Yu; DanYang Shi; Si Liu; Zheng-Wei Gong; Shuang Wang; ZhiWei Sun
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

10.  Characterization of new formalin-detoxified botulinum neurotoxin toxoids.

Authors:  James E Keller
Journal:  Clin Vaccine Immunol       Date:  2008-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.